Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS) is a Biotechnology company in the Healthcare sector listed on the NYSE.

As of Oct 23, 2026: market cap $42.3M; returns 1 day +0.8%, 1 week +0.6%, 1 year -50.5%.

Annovis Bio, Inc. (ANVS) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease. Their lead drug candidate, Buntanetap (ANVS401), is a translational inhibitor of neurotoxic aggregating proteins (TINAPs) currently undergoing Phase 3 trials.

Groups ANVS belongs to

• Clinical Stage Biotech
• Biotechnology
• Neuroscience
• Biopharmaceutical
• CNS Disorders
• Neurological Disorders
• Alzheimer's Disease
• Healthcare
• Life Sciences
• Clinical Stage
• Pharmaceuticals
• Drug Discovery

ANVS financial model: income statement, cash flow and balance sheet